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the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement and HEOR issues associated
with regenerative medicines. RESULTS:Although considered a nascent field, over
40 HTAs and coverage policies on cellular therapies and regenerative medicines
were available from the key Australian, European and North American HTA
agencies and payers considered in the assessment. Many of HTAs and coverage
policies identified gaps in effectiveness data, particularly the lack of compelling
comparative trials and long-term outcomes, and uncertainty surrounding
cost-effectiveness. CONCLUSIONS: While HTAs and payer policies on regenera-
tive medicines reflected decision factors commonly associated with biopharma-
ceuticals, other key market access factors beyond clinical- and cost-effectiveness
were identified that are specific to this field. These factors include involvement of
multiple reimbursable technologies in cell extraction, processing and administra-
tion; cell handling steps that may engage multiple healthcare budgets; and require-
ments to characterize the value of the entire procedure versus the regenerative
medicine alone. Key considerations for HEOR and market access planning are con-
sidered.
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OBJECTIVES: The diffusion of innovative technologies and specifically the differ-
ence between early and mainstream adopters during the product’s life-cycle (also
known as the chasm/saddle phenomena), has been studied empirically. It has been
demonstrated that given a dual-market structure (e.g. early vs. mainstream adopt-
ers) cost has a substantially higher negative impact on mainstream adoption rate
than on early adoption rate. Previous studies focused primarily on the consumer
electronics industry. We examined whether the phenomena of dual-markets ex-
ists also for medical technologies. METHODS: We analyzed the diffusion of inno-
vation patterns of 11 medical interventions using a recent mathematical model:
the Change of Dominance (CD) model, which analyzes the dynamics between the
early and mainstream adopters. Previous research concluded that influences on
adoption and subsequent diffusion rates are very different for various health cat-
egories, technologies, and geographies. Therefore, our empirical dataset covered
three major medical intervention categories: interventional procedures (e.g. coro-
nary stents), pharmaceuticals (e.g. beta-blockers), and diagnostic technologies (e.g.
CT scans). The dataset was collected from five countries: United States, UK, Korea,
Canada and New Zealand.RESULTS:The CD model has an excellent fit (90%) to all
of the technologies analyzed. Nine of the 11 technologies examined (82%) reached
major market adoption. The median time of change of dominance for these nine
technologies was seven years, very similar to that found for consumer electronics.
The adoption rate at the time of CD is 25%, which is higher than the rate in
consumer electronics markets. The CD time of interventional technologies (e.g.
coronary stents, bypass surgery) was substantially lower (3 vs. 8.5 years) compared
to pharmaceuticals or diagnostic technologies. CONCLUSIONS: The dual market
phenomenon seems to occur in the health care, with similar patterns to the con-
sumer electronics industry. Both technology manufacturers and health planners
should consider these findings when attempting to promote the use of innovative
technologies.
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OBJECTIVES: The literature indicates that the expenditure on orphan drugs will be
increasing over the coming years. The market for orphan drugs has inherent mar-
ket characteristics that sometimes result in high prices. The aim of this study was
to analyse whether awarding orphan designation status has an influence on the
price setting of drugs for rare disease indications. METHODS: To this effect, prices
of designated orphan drugs were compared with other non-designated drugs for
rare disease indications. We identified 28 designated orphan drugs and 16 compa-
rable non-designated drugs for rare disease indications for which we collected
official hospital prices (per defined daily dose) in Belgium in 2010. RESULTS: Or-
phan-designated drugs had a higher median price (€138.56 [interquartile range; IQR
€406.57]) than non-designated drugs (€16.55 [IQR €28.05]) for rare disease indica-
tions (p  0.01). CONCLUSIONS: In conclusion, our results suggest that awarding
orphan designation status in itself is associated with higher prices for drugs for rare
disease indications. In order to gain full insight into orphan drug pricing mecha-
nisms, future research should focus on collecting information about the different
factors influencing orphan drug pricing.
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OBJECTIVES: The pharmaceutical-sector is vital for the society and economy as a
whole. Wholesalers are essential for the distribution-chain because they bridge
time and space between supply and demand. Thus, the study aims to draw a
comprehensive picture of the Pharmaceutical-Wholesale-Industry, outlining its
socio-economic importance compared to other forms of distribution with qualita-
tive and quantitative methods, focusing on Germany, U.K., France, Italy, Spain and
the The Netherlands. METHODS: The necessary data was obtained from different
sources: an online-questionnaire was directed to pharmacies, annual GIRP and
IMS-Health statistics; a questionnaire was directed to GIRP-full-member associa-
tions and Wholesale companies (return rate 81%); and systematical literature re-
search which verified the empirical findings. RESULTS: If pooling of medicines
would not be ensured by Wholesalers, each pharmacy would have to contact each
Manufacturer in order to obtain a complete assortment of medicines. The contin-
uous supply of medicines involves more than 4.5bn transactions between Pharma-
cies, Wholesalers and Manufacturers each year. Without Wholesalers this number
would dramatically increase to 99.4bn transactions per year. On average Whole-
salers are bundling products of 21.84 Manufacturers per delivery. The process-
costs of a several order from Wholesalers are €7.98; from Manufacturer €11.36 (cost
differences of 21.84 supplies from direct sales: €240.11). These additional costs have
to be paid by Manufacturers, Pharmacies and finally by Patients. Furthermore,
Wholesalers pre-finance (Ø €11.5bn for 46d) the entire medicine-market and secure
the cash-flow of the social-insurers. Regarding satisfaction with different distribu-
tion-models, the results of the online-questionnaire show that pharmacists are not
satisfied with the new models (satisfaction Wholesalers: 85.17%; Manufacturer:
39.75%; RWA: 9.50%; DTP: 12.2%). CONCLUSIONS:A reduction in number of Whole-
salers will result in a slower supply of medicines, so the existence of the current
distribution system is vital to the European health care sectors, as Pharmaceutical
Wholesalers help reducing transaction-cost, secure a safe, rapid and continuous
supply of medicines.
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OBJECTIVES: To describe the evolution of biosimilars in the EU Member States (MS)
and to identify the key parameters of the EU biosimilars market dynamics across
countries: time to market entry, prices and market penetration. METHODS: A
quantitative analysis of the EU biosimilar market from 2007 to 2010 was conducted
for 26 EU MS. Data was obtained from European Medicines Agency (EMA) and IMS
MIDAS database, including at country level: Date of market entry of reference
products and biosimilars, unit sales and prices (estimated using official prices) of
existing biosimilars and their respective reference products. Descriptive statistics
were applied to summarize the results. Multivariate regression analysis was ap-
plied to identify statistical associations between: 1) time period between the EMA’s
approval and market entry; 2) market penetration (in monetary value); 3) biosimi-
lars DDD prices and the following independent variables: Pharmaceutical market
value, population, Gross National Income, Price Level Index of medicines, total
expenditure on health as % GNI, total expenditure on health in absolute terms,
government expenditure on health and Generic Price Control, International Price
Comparison, Tendering-like practices, Pharmacists generic substitution, INN pre-
scribing, Procedure for pricing and/or reimbursement decision, and Reference Price
System. RESULTS: The market penetration of biosimilars for the three reference
molecules (somatropin, epoietin and filgrastim) rose from 0.33% in 2007 to 15,52%
in 2010. The multivariate analysis show an association between the price level
index, the total and governmental expenditure on health and an earlier market
entry. CONCLUSIONS: Biosimilars hold a certain promise to help bring down the
cost of biologicals to health systems. Existing evidence in the EU is still limited and
the results do not show a clear pattern of market dynamics, although it becomes
evident that biosimilars will attain smaller price reductions and market penetra-
tion than conventional generics.
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OBJECTIVES: To review economic evidence supporting Rx-to-OTC switches.
METHODS: A systematic search of the EMBASE, Pubmed, ISPOR conference ab-
stracts databases and industry associations websites was conducted. The search
was limited to years 2000–2010 and to North America and European countries. Two
independent reviewers selected eligible studies. RESULTS: The search identified 14
reviews, 12 model publications, 12 database analyses, 5 prospective observational
studies and 11 other. Most articles originated from the US. In 5/6 database analyses
and in 8/9 budget impact models (BIM) that quantified cost consequences of Rx-to-
OTC switching, it was shown to generate savings to healthcare budget holders,
mainly due to Rx-drug acquisition savings. Other key direct savings included
avoided: doctor’s visits to obtain a prescription; emergency room visits or hospi-
talisations due to easier access to an effective or safer therapy. Employers’ benefits
included less time-off work to obtain a prescription and less absenteeism and
presenteeism due to easier access to therapies that improve employee productiv-
ity. Cost consequences of potential misuse due to lack of doctor’s supervision were
frequently acknowledged but rarely quantified. The key factors determining the
extent of savings were: uptake rates of the OTC drug among different types of
populations (i.e. those on Rx drugs, other Rx drugs, OTC-treated, untreated and
undiagnosed), therapeutic area and presence of disreimbursement policies. The
only European BIM is old (2004) and showed potential annual savings of €16.4
billion, assuming that 5% of Rx drugs are switched to the OTC status. However, its
use is limited as it is not specific to any drug/disease area and took a simplistic
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